INTERVIEW: New Angle for CTC capture device Parsortix; approval within a year?
This article was originally published in Clinica
Executive Summary
Parsortix, a blood-based diagnostic that captures and counts circulating tumour cells (CTCs) for the diagnosis, prognosis and monitoring of cancer, could be approved in around a year, according to Angle, the company developing the device.